Iran breaks German monopoly in type 2 diabetes drug
Iran breaks German monopoly in type 2 diabetes drug
An Iranian pharmaceutical company produced a drug to treat type 2 diabetes which was exclusively confined to Germany.
Sales manager of Abidi Pharmaceutical Co. Reihaneh Rouhani, while pointing to the unveiling process of Sitagliptin with brand name Ziptin to treat type 2 diabetes, said Iran could break the monopoly of Ziptin drug already produced by a German Co.